| Compound | BPC-157 + GHK-Cu + KPV |
|---|---|
| Category | Vendor blend (healing peptides) |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers BPC-157 + GHK-Cu + KPV, a vendor blend (healing peptides), graded "Minimal evidence" in this catalog's evidence system. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A three-way vendor blend combining BPC-157 with the copper peptide GHK-Cu and the tripeptide KPV, marketed for combined "healing and anti-inflammatory" use without trial support.
Mechanism of Action
Stacked mechanistic rationale as with other blends; no interaction data exist for the combination.
Research and Evidence
No published studies — human or animal — evaluate this specific combination.
Safety and Side Effects
Same category risks as other unregulated blends: unknown composition, no safety database.
Frequently Asked Questions
What is the evidence tier of BPC-157 + GHK-Cu + KPV?
BPC-157 + GHK-Cu + KPV is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is BPC-157 + GHK-Cu + KPV an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for BPC-157 + GHK-Cu + KPV?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — no combination trials registered. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.